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On 1st April 2019 the National Institute for Health and Care Excellence (NICE) will be 20 
years old. This is an anniversary worth noting, if for no other reason than how remarkable it 
is for an NHS quango (quasi-autonomous non-governmental organisation) to be still 
standing two decades after its inception. There are more reasons for marking and 
celebrating NICE’s 20-year run. In the intervening years, the Institute has done much to 
advance the health of the UK population. It has achieved an international reputation for 
robust and fair health care prioritisation that is widely viewed as setting the global standard. 
NICE built this reputation not only through the rigorous development and application of 
scientific methods to guide its work, but also through its efforts to articulate the underpinning  
social and ethical values that provide its decisions with robust justification. NICE’s reputation 
also rests on its commitment to transparency, accountability and inclusiveness in facilitating 
public and patient input in its deliberations.  
From the start, NICE developed a distinctive approach to its work. The Institute took a robust 
view on the need to provide evidence for the value of health care interventions.  In a publicly-
funded but cash-limited system, citizens (and politicians) needed to be assured that the NHS 
would only fund interventions that provided good value for money. Yet, NICE went beyond 
these generalities to specify how value for money would be assessed. NICE considered 
whether the opportunity costs of investing in new interventions could be justified by the 
health gains they could offer. A threshold was set – a range of £20,000 to £30,000 per 
additional quality-adjusted life-year (QALY) – above which a new intervention would not 
normally be considered a ‘good buy’ for the NHS and rejected because its adoption would 
likely displace more health than it offered. As a way of publicly justifying its decision-making 
processes, NICE developed a statement of what it termed its “Social Value Judgements” 
(SVJ) in 2005 (1). This document was updated in 2008, in response to NICE acquiring 
responsibilities for public health. Both editions focused on value for money as a foundational 
consideration for ensuring fairness to NHS patients in the context of limited resources. As a 
testimony to SVJ’s importance, the document was cited in the first judicial review of a NICE 
decision: "The key principle underlying NICE’s approach to appraisals is that the NHS’s 
limited resources should be targeted on those treatments which provide best value for 
money. The principle is to be found at paragraph 4.1 of NICE’s “Social Value Judgments – 
principles for the development of NICE Guidelines” (8th December 2005)” (2).  
Although the SVJs clearly conveyed NICE’s commitment to securing value for money, they 
also recognized the critical importance of other social and ethical values. Reducing health 
inequalities, preventing discrimination, and addressing disabled people’s needs figured 
prominently in both SVJ documents.  So, when NICE announced in November 2018 that it 
was updating SVJ, there was considerable interest in whether any changes would ensue - 
2 
 
perhaps reflecting the increasing personalisation of medicine or how NICE was adapting to 
the addition of social care to its remit, within a global environment of healthcare austerity, 
scepticism of expertise, and, of course, Brexit (the UK referendum decision to leave the 
European Union) (3).  
Against this backdrop, the current consultation document, “The principles that guide the 
development of NICE guidance and standards” is puzzling. This short document is not just a 
revision of principles but implies a wholly different approach to the application of the social 
and ethical values thought to be relevant to NICE’s work. It is pitched entirely on the 
procedural principles that govern how NICE works. While important, these are no substitute 
for the underlying substantive social and ethical values that NICE is committed to help 
secure. Table 1 highlights the key values of the existing and proposed versions of SVJ. The 
absence of any specific commitments or reference to substantive social or ethical values in 
the proposed version is remarkable.  
 
(Table 1 here)   
 
Both the 2005 and 2008 versions of SVJ begin with a discussion of the substantive 
bioethical and procedural operating principles which govern NICE decision-making. This is 
absent in the proposed revision. Substantive values present in the earlier versions - notably 
fairness, equality and respect for autonomy - have now dropped out altogether. 
NICE’s rationale for this dramatic change is that all the values relevant to NICE are available 
in other documents. These documents include the NICE Charter, its process and methods 
manuals, and legal and establishment materials—in total many hundreds of pages whose 
content is, for the most part, highly technical. NICE’s social and ethical values may be 
implicit in these documents, but they are by no means explicit, and they certainly require 
interpretation. NICE also claims, questionably, that its values are “after almost 2 decades, 
well understood and accepted” (3).  
This change raises two questions. First, what is lost when substantive ethical and social 
values, like those endorsed in both prior SVJs, are no longer explicitly put forward as guiding 
principles for NICE? Second, what is the impetus for and objective of this dramatic change – 
could it be heralding a shift in the way NICE thinks or works? 
Considering the first question, the main casualties of this new approach are likely to be 
accountability, transparency, consistency, and public, political and professional 
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understanding of the reasons for NICE’s decisions. The move away from substantive ethical 
values towards procedural principles enables the detail of decision-making procedures and 
the content of recommendations to remain almost entirely unspecified. Patients who are 
being denied treatment on the basis of NICE’s decisions will particularly struggle to make 
sense of their situation, as will clinicians who need to explain such decisions to them. 
Equally, NICE’s decisions are left open to a wide range of professional, financial, political 
and other interests without providing a basis for scrutinising them. For these reasons, the 
move towards procedural principles sends a worrying signal to other countries who are 
establishing priority-setting processes for Universal Health Coverage (UHC). UHC is about 
the values and principles that countries could embrace in expanding health benefits for their 
populations. With the proposed SVJ, NICE risks losing its status as a leading example from 
which others might learn how to combine procedural and substantive values in decision-
making.  
While goals such as reducing health inequalities are embedded in NHS legislation, to be 
meaningful and actually addressed, they must be enacted in the day-to-day functioning of 
NICE and other health and care organisations. Furthermore, although the historical divide 
between health and social care is becoming more blurred, this should not lead to an 
assumption that challenges in both areas are similar. Rather, analysis of the challenges and 
opportunities in the two areas working in a more integrated fashion is required. NICE has 
been responsible for developing social care guidance since 2013 but, according to the 
proposed SVJ, this does not seem to have prompted reconsideration of the way it might 
function in the future, even though a NICE Citizens Council discussion in 2013 suggested 
there could be some differences, in emphasis at least, in the areas of dignity and respect for 
autonomy (4). Applying a consistent set of principles to both sectors together with clearly 
identified research priorities for the National Institute for Health Research (NIHR) would 
enhance both the way NICE approaches these interrelated decisions and the availability of 
empirical data, especially relating to outcome measurement, valuation, costing and inequity 
reduction.  
Other flagships of NICE’s methods, for example how “evidence” is defined and assessed, 
are also given little attention. While its invocation of the use of “relevant, reliable and robust 
evidence” seems uncontroversial, it says nothing about how NICE will approach the 
contestable nature of the interpretation of these attributes. Simply signposting interested 
parties to the technical and process manuals might be considered efficient, but it is 
analogous to inviting people to read the New Testament in order to identify key Christian 
values.   
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With regards to the second question - what is the impetus for and objective of this dramatic 
change in guiding principles for NICE? The Institute is no longer the dominant provider of 
NHS guidance - NHS England is increasingly issuing clinical guidance either directly or in 
collaboration with NICE, for example, in the case of the Cancer Drugs Fund (5). Public 
health guidance is now frequently developed by Public Health England. Within this crowded 
space, there are hints that NICE’s methodology is changing to accommodate broader goals 
(6). The previous emphasis on cost-effectiveness as a social and ethical value and the use 
of an explicit cost-effectiveness threshold are watered down to the somewhat inexact 
“assessment of population benefits and value for money” (Principle 6 in the new document). 
This vagueness may be mere drafting for a general audience or it could represent a drift 
towards greater managerial discretion and control. Specifically, this could reflect a 
weakening of the application of the threshold – either upwards to the benefit of industry or 
downwards for the sake of expenditure control. Both have consequences for the fair 
distribution of people’s health (7). 
So what is the way forward?   NICE has a responsibility not only to ensure that its social and 
ethical values are explicit and aligned with the goals of the NHS, public health and social 
care (8,9) but how they are made a day-to-day reality. This new document does little to 
achieve this: it would be better to withdraw it and start work on a thorough revision of SVJ. 
Alternatively, NICE published a Charter in 2017 (10) that has a short section on social and 
ethical values. This could be expanded. 
As a group of observers and admirers of NICE, we are disappointed that the proposed SVJ 
document departs from many of the values that made NICE such an innovative and widely-
admired organisation. NICE and the NHS are currently under immense pressure, but now is 
not the time for retreat from substantive values. This is the time for NICE to reaffirm these 
values and seize again its global leadership role as an institution that brings accountability, 
transparency and legitimacy to decisions that are among the most ethically and politically 
challenging in any society.  
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